1-6 of 6
Kathryn J. Newhall
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)

Jeremy S. Abramson, Aravind Ramakrishnan, Ana Alfonso Pierola, Ira Braunschweig, Guillaume Cartron, Catherine Thieblemont, Jose A. Pérez-Simón, Pere Barba, Peter A. Riedell, Carlos Solano, Thomas Gastinne, Alexandra LaCroce, Denise Thomas, Camille Poirot, Sarah Meadows, Kathryn J. Newhall, Daniel J. Lee, Mark G. Frattini, Emmanuel Bachy
Journal: Blood
Blood (2023) 142 (Supplement 1): 2110.
https://doi.org/10.1182/blood-2023-186570
Published: 2023
Journal Articles

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J Curran, Stephan Grupp, Andre Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana B. Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel
Journal: Blood
Blood (2023) 142 (Supplement 1): 4847.
https://doi.org/10.1182/blood-2023-187252
Published: 2023
Journal Articles

The Broad Activity of the CD33/CD3 Bispecific BiTE® Antibody AMG 330 in Primary Human AML Is Impacted By Disease Stage and Cytogenetic/Molecular Risk

Kimberly H. Harrington, BS, Chelsea J. Gudgeon, BS, George S. Laszlo, PhD, Kathryn J. Newhall, PhD, Angus M. Sinclair, PhD, Stanley R. Frankel, MD, Roman Kischel, MD, Guang Chen, PhD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2014) 124 (21): 266.
https://doi.org/10.1182/blood.V124.21.266.266
Published: 2014
Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD
Journal: Blood
Blood (2014) 124 (21): 986.
https://doi.org/10.1182/blood.V124.21.986.986
Published: 2014
Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD
Journal: Blood
Blood (2014) 124 (21): 3738.
https://doi.org/10.1182/blood.V124.21.3738.3738
Published: 2014
Journal Articles

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

George S. Laszlo, Chelsea J. Gudgeon, Kimberly H. Harrington, Justine Dell’Aringa, Kathryn J. Newhall, Gary D. Means, Angus M. Sinclair, Roman Kischel, Stanley R. Frankel, Roland B. Walter
Journal: Blood
Blood (2014) 123 (4): 554–561.
https://doi.org/10.1182/blood-2013-09-527044
Published: 2014
Includes: Supplemental data